Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
A Phase I Trial
Darryl P. Leong, Tammy Cosman, Muhammad M. Alhussein, Nidhi Kumar Tyagi, Sarah Karampatos, Carly C. Barron, Douglas Wright, Vikas Tandon, Patrick Magloire, Philip Joseph, David Conen, P.J. Devereaux, Peter M. Ellis, Som D. Mukherjee and Sukhbinder Dhesy-Thind
Number of Trastuzumab Doses Received Before and After Enrollment, by Participant ID
Participants #5 and #11 discontinued trastuzumab permanently because of cardiac dose-limiting toxicity. Participant #19 completed treatment after 12 months of trastuzumab, amounting to 17 cycles; there was no plan to administer 18 cycles to this participant.